Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca, Lilly, Novo Look To China Growth Despite Pricing Headwinds – Emerging Market Earnings Roundup (Part 1)

May 01 2012

• By Brian Yang

Related Content

Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

Jan 11 2011

AstraZeneca’s Nexium, GSK’s Zofran Among Latest Victims Of China Price Cuts; NDRC Plans Further Pricing Reforms To Encourage Innovation

Apr 06 2012

Brennan’s Departure Not Expected To Disrupt Current Business Development Strategy At AstraZeneca

Apr 30 2012

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity

Nov 03 2011

As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets

Sep 07 2010

Related Companies

AstraZeneca PLC

Eli Lilly and Company

Novo Nordisk A/S

AstraZeneca PLC

Aurobindo Pharma Limited

Intas Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Ardea Biosciences, Inc.

Boehringer Ingelheim GmbH

Additional Topics

Asia Pacific Strategy Emerging Markets BioPharmaceutical

More from Focus On Asia

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window